Results 181 to 190 of about 3,855,282 (269)

Barriers to Health Care and Cancer Screening.

JAMA Netw Open
Gurayah AA, An A, Kuchakulla M, Morley F, Markowitz DM, Mao J, Davuluri M, Al Awamlh BAH, Nanus DM, Tamimi RM, Kensler KH.   +10 more
europepmc   +1 more source

Health Care Utilization in Adults With Congenital Heart Disease: Population-Based Findings. [PDF]

Birth Defects Res
Crume TL, Khanna AD, Tillman A, Lui GK, Soim AS, Hsu DT, Sommerhalter K, Sullivan A, Li JS, D Ottavio A, Book WM, Raskind-Hood C, Whitehead K, Pinto N, Feldkamp ML, Reeder MR, Krikov S, Botto LD.   +17 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Screening by Health Care Systems for Barriers to Patient Engagement With Digital Health Care: Cross-Sectional Survey Study. [PDF]

JMIR Form Res
Shih JJ, Yang A, Kwok VE, Sheon AR, Ellis RL, De Marchis EH, Diamond LC, Dy M, Lyles CR, Ma C, Shah ND, Natsuhara KH, Rahman SB, Rodriguez JA, Sarkar U, Sharma AE, Khoong EC.   +16 more
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Video consultations for dentistry in primary health care: a pilot study. [PDF]

Front Oral Health
Perez-Heredia M, Aparicio-Mota A, Jiménez-Rodríguez D.   +2 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

What do health insurance deductibles do to health care spending growth? [PDF]

Int J Health Econ Manag
Lucarelli C, Frean M, Gordon AS, Hua LM, Pauly MV.   +4 more
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

The Use of Speculative Fiction in Future-Focused Health Care Research. [PDF]

J Med Internet Res
Groeneveld S, Wentzel J, Laurens M, Gemert-Pijnen LV, Verdaasdonk RM, Os-Medendorp HV, Ouden MD.   +6 more
europepmc   +1 more source